A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.

Also called NCT07625215

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 360 participants (planned count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07625215
  • EU CT 2025-523807-31-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Bulgaria, Germany, Hungary, Italy, Netherlands, Poland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07625215. Randomized; double masking; primary purpose treatment. Start 2026-09-01 (actual); primary completion 2030-05-16 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
Acronym
CARDIOVERT
Intervention (Drug)
BAY 3670549
Intervention (Other)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct07625215
Content hash
6d03f18c0ba3b6fd3a1f3b1ed71912f57068494649c8b88986d0ab052b54e430